You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,846,632


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,846,632
Title:Nucleic acids for targeting multiple regions of the HCV genome
Abstract: Compositions and methods effective for modulating Hepatitis C viral infection are provided.
Inventor(s): Couto; Linda B. (Pleasonton, CA)
Assignee: The Children\'s Hospital of Philadelphia (Philadelphia, PA)
Application Number:13/602,886
Patent Claims:1. A composition comprising a miRNA expression cassette comprising a cluster sequence selected from the group of consisting of cluster 1, cluster 2 and cluster 5.

2. The composition of claim 1, wherein said cluster sequence is cluster 5.

3. The composition of claim 1 or claim 2, wherein said cluster sequence is contained in a vector.

4. The composition of claim 3, wherein said vector is selected from the group consisting of AAV vectors, lentiviral vectors, retroviral vectors and AV vectors.

5. The composition of claim 4, wherein said vector is an recombinant AAV vector having a serotype selected from the group consisting of AAV-2, AAV-6 and AAV 8.

6. The composition of claim 3, wherein the expression of nucleotides is under the control of a single promoter.

7. The composition of claim 6, wherein said promoter is a tissue-specific promoter.

8. The composition of claim 7, wherein said promoter is a liver-specific alpha-one antitrypsin promoter, said composition additionally comprising a liver-specific enhancer and a polyadenylation signal.

9. The composition of claim 8, wherein said enhancer is the apolipoprotein E hepatic control region.

10. The composition of claim 8, wherein said polyadenylation signal is the bovine growth hormone polyadenylation signal.

11. The composition of claim 3, wherein said composition comprises an intron.

12. The composition of claim 11, wherein said intron is downstream of said promoter and upstream of said cluster.

13. The composition of claim 12, wherein said intron is derived from human growth hormone.

14. A method of reducing HCV viral load in a patient comprising administering to the liver of said patient a therapeutically effective amount of the composition of claim 3 which directs cleavage of target HCV mRNA sequences present in said patient, thereby reducing HCV viral load.

15. The method of claim 14, wherein said composition is introduced directly into said patient.

16. The method of claim 15, wherein said introduction is via intravenous infusion.

17. The method of claim 14, wherein said method results in inhibition of HCV replication in said patient.

18. The method of claim 12, wherein introducing the vector to a cell, tissue, or organ of interest comprises: ligating the miRNA cassette into a viral delivery vector to form a viral miRNA expression construct; packaging the viral miRNA expression construct into viral particles; and delivering the viral particles to the cell, tissue, or organ of interest.

19. The method of claim 18, wherein the miRNA cassette comprising nucleic acids which target multiple regions of a HCV genome.

20. The method of claim 19, wherein said vector is an AAV vector and the miRNA cassette is cluster 5.

Details for Patent 8,846,632

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2030-03-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2030-03-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2030-03-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.